<DOC>
	<DOCNO>NCT02413346</DOCNO>
	<brief_summary>Open-label study evaluate safety approximate 1.5 mg/kg/day dose oral sarecycline long-term treatment subject moderate severe facial acne vulgaris .</brief_summary>
	<brief_title>A Multi-Center Open-Label Evaluation Safety Sarecycline Tablets Treatment Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Successfully complete participation Phase 3 study saracycline ( SC1401 SC1402 ) Signed informed consent assent form Body weight 33 kg 136 kg , inclusive Negative urine pregnancy test female childbearing potential Agrees use effective method contraception throughout study , applicable . Able fulfill protocol requirement , indicate willingness participate study agree study procedure provide write informed consent/assent authorization disclose ( personal health information ) Currently participate another clinical study , unless pharmacokinetic sarecycline study participation approve medical monitor ; receive investigational medication ( except sarecycline ) within 30 day enrollment . Discontinued participation Phase 3 study sarecycline reason Had poor compliance wtih study requirements/study drug dose Phase 3 study sarecycline Is receiving/planning receive systemic acne medication , systemic retinoids , systemic corticosteroid androgen/antiandrogenic therapy ( eg , testosterone , spironolactone ) Is pregnant , lactate plan pregnancy study period Has significant intercurrent illness ( include clinically significant abnormality clinical laboratory test ) , psychiatric disorder , factor , opinion Investigator Medical Monitor , preclude participation study Is judge Investigator unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>